I-Tind for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia: Mid-term outcomes from a multicenter cohort

Dimitri M, Calarco A, Filippi B et al. Urologia. 2025;0(0). Online ahead of print.

Patients experienced significant improvement in urinary flow and symptom scores at all time points up to 12 months following the iTind device implantation.

IPSS decreased from a baseline of 21.5 ± 5.1 to 9.7 ± 5.5 at 12 months, and IPSS-QoL score improved from 6.0 ± 2.5 to 3.9 ± 0.8 ($P < 0.001$).



Abbreviations: IPSS (International Prostate Symptom Score); QoL (Quality of Life); Qmax (Maximum urinary flow rate); PVR (Post-Void Residual volume).

Objective

To assess the safety, efficacy, and functional outcomes of the iTind procedure over a 12-month period in men with symptomatic benign prostatic hyperplasia (BPH) unresponsive to alpha-blocker therapy, in a retrospective, single-arm, multicenter study design.

Results

- Study included 120 patients that underwent successful iTind device implantation; all were discharged the same day. The mean patient age was 52.9 (±7.9) years, and the average prostate volume was 40.5 mL (±12.25).
- From baseline to 12 months, Qmax increased from 7.6 ± 2.6 to 15.7 ± 7.1 mL/s ($P < 0.001$), and PVR decreased from 72.3 ± 35.2 to 62.5 ± 15.9 mL ($P < 0.0001$).
- All implants were retrieved after 6.1 ± 0.9 days; three cases of incomplete closure were reported, and one was linked to a fibrous adenoma.
- Sexual and ejaculatory functions were fully preserved.
- Durability and patient selection need long-term study confirmation.

Conclusion

The study results confirm that temporary implantation of the iTind device is a safe and effective solution for alleviating BPH symptoms, with lasting benefits seen at 12 months. Additionally, sexual and ejaculatory functions were fully preserved.

Product: The iTind Procedure.

Link to Publication

OLYMPUS EUROPA SE & CO. KG
Postbox 10 49 08, 20034 Hamburg, Germany
Wendenstrasse 20, 20097 Hamburg, Germany
Phone: +49 40 23773-0, Fax: +49 40 233765
www.olympus-europa.com

As medical knowledge is constantly growing, technical modifications or changes of the product design, product specifications, accessories, and service offerings may be required. Medical devices listed may not be available for sale in all countries.

M/S S00723 EN V01• 09/25 • OEKG
Olympus Scientific Affairs